Glenmark gets tentative nod from USFDA for migraine tablets

NEW DELHI: Glenmark Pharmaceuticals today said it has received tentative approval from the US health regulator for its generic Rizatriptan Benzoate tablets used for treating migraine attacks.

The company's US arm Glenmark Generics Inc USA has received tentative approval for Rizatriptan Benzoate tablets from the US Food and Drug Administration (USFDA), Glenmark Pharmaceuticals said in a statement.

The tablets are generic version of drug major Merck's Maxalt tablets, it added.

Quoting IMS Health data, the company said Rizatriptan Benzoate immediate release tablets achieved sales of $315 million for the 12 month period ending June 2012.

Current portfolio of the company consists of 81 products authorised for distribution in the US market and 41 abbreviated new drug applications (ANDAs) pending approval with the USFDA.

Shares of Glenmark Pharmaceuticals were trading at Rs 416 per scrip on BSE in the afternoon trade, up 0.96 per cent from its previous close.